REFERENCES
TABLE
AND FIGURE CAPTIONS
Figure 1. PRISMA diagram for the literature review.
†Number of studies included from the original SLR does not align with
the original SLR report because pooled studies excluded in the original
SLR were re-reviewed, and those reporting novel data in prior treatment
failure subgroups have now been included in the SLR.
Abbreviations: HTA, Health Technology Assessment; PRISMA, Preferred
Reporting Items for Systematic Reviews and Meta-Analyses; SLR,
systematic literature review.
Figure 2. Graphical illustration of the meta-regression showing
relationship between placebo reduction in monthly migraine days and
treatment failures with subcutaneous administration for (A) episodic
migraine and (B) chronic migraine.
Abbreviations: MMDs, monthly migraine days.
Table 1. Placebo response in clinical trials of anti-CGRPs.
†Subgroup analysis of patients with ≥2 prior treatment failures.
‡Study included both episodic and chronic migraine; analysis population
includes patients with episodic migraine only.
§Study included both episodic and chronic migraine; analysis population
includes patients with chronic migraine only.
Abbreviations: CGRP, calcitonin gene-related peptide; IV, intravenous;
MMDs, monthly migraine days; SE, standard error.
Table 2. Relationship between MMDs reduction and subcutaneous
treatment failures (3,592 total patients, EM and CM trials).
Abbreviations: CI, confidence interval; CM, chronic migraine; EM,
episodic migraine; MMDs, monthly migraine days; SE, standard error.
Table 3. Placebo reduction in MMDs with administration route,
migraine type, and percentage of patients as covariates.
†Chronic migraine was used as the reference value.
Abbreviations: CI, confidence interval; IV, intravenous; MMDs, monthly
migraine days; SE, standard error.